Takahiro Nigawara

This inventor holds 8 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Astellas Pharma Gmbh, Tenvie Therapeutics, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takahiro Nigawara. Retrieved from https://idiyas.com/inventor/takahiro-nigawara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 10.2

ph-index = 3

Forward Citations = 44(Granted Patents)

Company Filing History:

Tenvie Therapeutics, Inc.

patent

Years Active: 2009-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741942 - Substituted pyridazine compound (2026-09-22),

2. 10774082 - Quinazoline compound (2020-09-15),

3. 10556906 - Quinazoline compound (2020-02-11),

4. 9585889 - Nitrogen-containing bicyclic aromatic heterocyclic compound (2017-03-07),

5. 9328118 - Nitrogen-containing bicyclic aromatic heterocyclic compound (2016-05-03),

6. 8329707 - Substituted pyrazine compounds (2012-12-11),

7. 7947690 - Pyrimidine derivative condensed with a non-aromatic ring (2011-05-24),

8. 7557112 - Aromatic-ring-fused pyrimidine derivative (2009-07-07),

Title: An Insight into the Innovations of Takahiro Nigawara

Introduction

Takahiro Nigawara is a prominent inventor based in Tokyo, Japan, recognized for his significant contributions to pharmaceutical innovations. With a total of 7 patents to his name, he has focused his research on compounds that serve crucial roles in treating complex medical conditions, particularly in oncology.

Latest Patents

One of Takahiro's most recent patents focuses on a quinazoline compound, designed to serve as an active ingredient in pharmaceutical compositions for treating lung cancer. The compound exhibits exceptional G12C mutation KRAS inhibitory activity, which makes it a promising therapeutic agent for lung cancer. The research leading to this invention spotlights the quinazoline compound's potential and emphasizes its medicinal value in oncology.

Career Highlights

Takahiro Nigawara's career is closely tied to his role at Astellas Pharma GmbH, where he contributes to groundbreaking pharmaceutical innovations. His work is characterized by a commitment to research that aims to address pressing health challenges through advanced drug development.

Collaborations

Throughout his career, Takahiro has collaborated with esteemed colleagues, including Masahiko Hayakawa and Kazuyuki Kuramoto. These partnerships have furthered his research efforts and enhanced the development of innovative pharmaceutical solutions.

Conclusion

In summary, Takahiro Nigawara's work embodies the spirit of innovation in the pharmaceutical industry. His patents, particularly those pertaining to quinazoline compounds, demonstrate a significant advance in the fight against lung cancer. As he continues his research at Astellas Pharma GmbH, the medical community eagerly anticipates further breakthroughs that could improve patient outcomes worldwide.

Profile summary based on public USPTO records.